Multiple Scientific Presentations at the San Antonio Breast Cancer Symposium Highlight the Clinical Utility of the Myriad myR...
December 09 2015 - 07:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, today announced it will
highlight three scientific presentations related to its myRisk
Hereditary Cancer test at the 2015 San Antonio Breast Cancer
Symposium (SABCS) in San Antonio, Texas. Data include results from
studies that advance the understanding of hereditary cancer testing
using multi-gene panels to evaluate patients at risk for or
diagnosed with breast cancer.
"Our collaborators will present data at SABCS this year that
show multi-gene panel testing with myRisk Hereditary Cancer
provides clinically significant results that drive appropriate
changes in patient care," said Johnathan Lancaster, M.D., Ph.D.,
chief medical officer, Myriad Genetic Laboratories.
"Importantly, there are new data that demonstrate the
positive perceptions from patients after they receive a multi-gene
test result. Furthermore, as we expand our testing to broader
gene panels and share scientific outcomes from our research
collaborations, important new questions are being asked that will
expand our thinking about exactly which patients should be tested
for hereditary cancer."
Details about the featured myRisk Hereditary Cancer
presentations at SABCS are below. Follow Myriad on Twitter via
@MyriadGenetics and stay informed about symposium news and updates
by using the hashtag #SABCS15.
myRisk Hereditary Cancer Poster
Presentations
- Title: Interim analysis of multiplex gene
panel testing for inherited susceptibility to breast cancer.
Date: Friday, Dec. 11, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster Discussion PD7-01.
Presenter: Dr. Gregory Idos, Stanford University
Cancer Institute.
This multi-center prospective study
was designed to analyze data from 2,000 patients undergoing
cancer-risk assessment using the myRisk Hereditary Cancer 25-gene
panel test. The objective was to determine the benefits of
multi-gene panel testing versus traditional genetic
testing. The interim analysis of the first 332 patients tested
found that 11 percent were positive for a deleterious
mutation. Among participants testing negative for BRCA1 and
BRCA2 mutations, the myRisk test identified deleterious mutations
in 14 patients, representing a 61 percent increase over BRCA
testing alone and prompting clinically appropriate risk reduction
recommendations and enhanced cancer surveillance. These
findings demonstrate the ability of the myRisk Hereditary Cancer
test to identify a subset of patients with deleterious mutations
who historically would have been missed by traditional genetic
testing for BRCA1/2 alone, and who could receive appropriate
medical management as a result.
- Title: The patient experience in a prospective
trial of multiple-gene panel testing for cancer risk.
Date: Thursday, Dec.10, 2015: 7:30 to 9:00 a.m.
CT. Location: Poster P2-09-07.
Presenter: Dr. Allison Kurian, Stanford University
Cancer Institute
In this study, 2,000 diverse patients
at risk for hereditary breast/ovarian cancer syndrome were
evaluated to determine the patient experience following genetic
testing with the myRisk Hereditary Cancer test. Patients were
surveyed at entry and three months after testing using the
Multidimensional Impact of Cancer Risk Assessment (MICRA)
scale. An interim analysis of the first 332 patients found
that 87 percent said they did not regret learning about the results
and 81 percent wanted all their genetic test results for all 25
genes tested. Although the study is ongoing, these interim
results suggest there is no evidence of an increase in cancer- or
testing-related distress/uncertainty after patients received their
test results.
- Title: Predisposing germline mutations in an
unselected academic breast cancer (BC) cohort.
Date: Wednesday, Dec. 9, 2015: 5:00 to 7:00 p.m.
CT. Location: Poster P1-08-07.
Presenter: Dr. Judy Garber, Dana-Farber Cancer
Institute
In this study, 456 patients newly
diagnosed with breast cancer were evaluated for mutations in 25
cancer genes using the myRisk Hereditary Cancer test. The
results show that 11 percent of the patients in a single academic
institution had a germline mutation in a breast cancer
predisposition gene. Approximately 7 percent were in BRCA1/2 genes
and 4 percent were in other cancer genes. Of the 49 women with
deleterious mutations associated with breast cancer, 21 (43
percent) were diagnosed after age 45. This finding suggests
that patients diagnosed with breast cancer at older ages may
benefit from genetic testing with the myRisk Hereditary Cancer gene
panel test.
For more information about these presentations, please visit the
SABCS website at https://www.sabcs.org/.
About Myriad myRisk™ Hereditary Cancer
Testing
The Myriad myRisk Hereditary Cancer test uses next-generation
sequencing technology to evaluate 25 clinically significant genes
associated with eight hereditary cancer sites including: breast,
colon, ovarian, endometrial, pancreatic, prostate and gastric
cancers and melanoma. For more information visit:
https://www.myriad.com/products-services/hereditary-cancers/myrisk-hereditary-cancer/.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad
discovers and commercializes molecular diagnostic tests that:
determine the risk of developing disease, accurately diagnose
disease, assess the risk of disease progression, and guide
treatment decisions across six major medical specialties where
molecular diagnostics can significantly improve patient care and
lower healthcare costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary cancer
testing markets, diversifying its product portfolio through the
introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to the clinical utility of the
Myriad myRisk™ Hereditary cancer gene panel test; multi-gene panel
testing with myRisk Hereditary Cancer providing clinically
significant results that drive appropriate changes in patient care;
new data demonstrating positive perceptions from patients
after they receive a multi-gene test result; the ability of the
myRisk Hereditary Cancer test to identify a subset of patients with
deleterious mutations who historically would have been missed by
traditional genetic testing for BRCA1/2 genes alone, and who could
receive appropriate medical management as a result; the findings of
the studies suggesting that patients diagnosed with breast cancer
at older ages may benefit from genetic testing with the myRisk
Hereditary Cancer gene panel test; the Company's commitment to
bringing transformative molecular diagnostics to people with
cancer; and the Company's strategic directives under the caption
"About Myriad Genetics." These "forward-looking statements"
are based on management's current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers'
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2015, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
CONTACT: Media Contact:
Ron Rogers
(908) 285-0248
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2023 to Mar 2024